Oral contraceptive pills containing drospirenone – a case report Case report

Main Article Content

Jacek Tomaszewski

Abstract

Contraceptive efficacy, treatment convenience, tolerability, incidence of adverse effects, safety and other medical benefits of combined hormonal contraception are key selection criteria of the best method birth control in women. Drospirenone, spironolactone analogue with antimineralocorticoid and antiandrogenic activities, counteracts the estrogen-induced stimulation of the renin–angiotensin–aldosterone system and blocks testosterone binding to androgen receptor. Combined oral contraception containing drospirenone is a safe option of birth control and offers other medical benefits: decrease salt and water retention, reduce or maintains a stable body weight, and lower of blood pressure. Partial antiandrogenic activity of drospirenone may counteract the negative effect of endogenous androgens on hair growth, acne, seborrhea, lipid changes, insulin, and possibly, body composition in women. Drospirenone + EE2 is the only COC with 3 indications: contraception and the treatment of premenstrual dysphoric disorder in women who wish to use a COC for birth control, and the treatment of moderate acne in teenage girls who are at least 14 years old, have achieved menarche and wish to use a COC for birth control.

Article Details

How to Cite
Tomaszewski, J. (2016). Oral contraceptive pills containing drospirenone – a case report. Medycyna Faktow (J EBM), 9(1(30), 74-78. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2274
Section
Articles

References

1. Oelkers W.H.: Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 2005; Suppl. 3: 19-27.
2. Batukan C., Muderris I.I.: Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006; 85: 436-440.
3. Bitzer J., Paoletti A.M.: Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin. Drug. Investig. 2009; 29: 73-78.
4. Oner G., Muderris I.I.: A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. Contraception 2011; 84: 508-511.
5. Caruso S., Cianci S., Malandrino C. et al.: Hyperandrogenic women treated with a continuous-regimen oral contraceptive. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013; 171: 307-310.
6. Buzney E., Sheu J., Buzney C., Reynolds R.V.: Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment. J. Am. Acad. Dermatol. 2014; 71: 859.e1-859.e15; quiz 873-9744.
7. van Zuuren E.J., Fedorowicz Z., Carter B., Pandis N.: Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst. Rev. 2015; 4: CD010334 [doi: 10.1002/14651858.CD010334.pub2].